The first described pathogenic variant c.2617G>T of the CFTR gene
https://doi.org/10.31146/2949-4664-apps-2-1-142-147
Abstract
Cystic fibrosis (CF) is a disease caused by pathogenic variants in the CFTR gene. The greatest difficulty at the moment is assessing the contribution to the development of the disease of rare and previously unidentified genetic variants (mutations), mutations of uncertain clinical significance, as well as determining the genotype-phenotype relationship. Additional diagnostic methods are needed due to the large number of patients with borderline sweat test values. Purpose of the study: to study the pathogenicity of a newly identified variant of the nucleotide sequence of the CFTR gene based on assessing the functional activity of epithelial ion channels (ENaC, CFTR, CaCCs). Materials and methods: medical history data, method intestinal current measurement (ICM). Results: the patient had a severe course of the disease. Positive sweat test results, low fecal pancreatic elastase. The ICM method showed the absence of chlorine channel function. Conclusion: For the first time, the clinical features of a patient with the c.2617G>T genetic variant in the genotype have been described. The results of the examination and the clinical course of the disease correspond to the severe course of the disease. Additional use of the ICM method confirmed the absence of CFTR channel function in a patient carrier of this variant of the CFTR gene.
About the Authors
Yu. L. Melyanovskaya
Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region; Research Center for Medical Genetics
Russian Federation
Russian Federation
E. I. Kondratyeva
Research Clinical Institute of Childhood of the Ministry of Health of the Moscow Region; Research Center for Medical Genetics
Russian Federation
Russian Federation
References
1. De Boeck K. Cystic fibrosis in the year 2020: A disease with a new face. Acta Paediatr. 2020 May;109(5):893-899. doi: 10.1111/apa.15155.
2. Mall M.A., Galietta L. J. Targeting ion channels in cystic fibrosis. J Cyst Fibros. 2015 Sep;14(5):561-70. doi: 10.1016/j.jcf.2015.06.002.
3. Castellani C., Duff A. J.A., Bell S. C. et al. ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 Mar;17(2):153-178. doi: 10.1016/j.jcf.2018.02.006.
4. Sherman V., Kondratyeva E., Kashirskaya N., Voronkova A., Nikonova V., Zhekaite E., Kutsev S. Newborn Screening for Cystic Fibrosis in Russia: A Catalyst for Improved Care.Int J Neonatal Screen. 2020 Apr 14;6(2):34. doi: 10.3390/ijns6020034.
5. Sherman V.D., Kutsev S. I., Izhevskaya V. L., Kondratyeva E. I. Effectiveness of neonatal screening for cystic fibrosis in the Russian Federation. Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2022; 17(3): 12-19. (In Russ.) doi: 10.20953/1817-7646-2022-3-12-19.@@ Шерман В. Д., Куцев С. И., Ижевская В. Л. Кондратьева Е. И. Оценка эффективности неонатального скрининга на муковисцидоз в Российской Федерации. Вопросы практической педиатрии. 2022; 17(3): 12-19. doi: 10.20953/1817-7646-2022-3-12-19.
6. Kass R. S. The channelopathies: novel insights into molecular and genetic mechanisms of human disease. J Clin Invest. 2005 Aug;115(8):1986-9. doi: 10.1172/JCI26011.
7. Katsanis S.H., Katsanis N. Molecular genetic testing and the future of clinical genomics. Nat Rev Genet. 2013 Jun;14(6):415-26. doi: 10.1038/nrg3493.
8. Petrova N.V., Kashirskaya N. Y., Vasilyeva T. A. et al. Analysis of CFTR Mutation Spectrum in Ethnic Russian Cystic Fibrosis Patients. Genes (Basel). 2020 May 15;11(5):554. doi: 10.3390/genes11050554.
9. Servidoni M.F., Gomez C. C.S., Marson F. A.L., Toro A. A.D.C., Ribeiro M. Â.G.O., Ribeiro J. D., Ribeiro A. F.; Grupo Colaborativo de Estudos em Fibrose Cística. Sweat test and cystic fibrosis: overview of test performance at public and private centers in the state of São Paulo, Brazil. J Bras Pneumol. 2017 Mar-Apr;43(2):121-128. doi: 10.1590/S1806-37562016000000076.
10. Mishra A., Greaves R., Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin Biochem Rev. 2005 Nov;26(4):135-53. PMID: 16648884
11. Graeber S.Y., Vitzthum C., Mall M. A. Potential of Intestinal Current Measurement for Personalized Treatment of Patients with Cystic Fibrosis. J Pers Med. 2021 May 8;11(5):384. doi: 10.3390/jpm11050384.
12. Minso R., Schulz A., Dopfer C. et al.Intestinal current measurement and nasal potential difference to make a diagnosis of cases with inconclusive CFTR genetics and sweat test. BMJ Open Respir Res. 2020 Oct;7(1): e000736. doi: 10.1136/bmjresp-2020-000736.
13. Union of Pediatricians of Russia; Association of Medical Genetics; Russian Respiratory Society; Russian Transplant Society; Association of Children’s Doctors of the Moscow Region. [Cystic fibrosis. Clinical guidelines]. 2021. ID: 372. (in Russ.)@@ Клинические рекомендации «Кистозный фиброз», 2021.
14. Derichs N., Sanz J., Von Kanel T., Stolpe C., Zapf A., Tümmler B., Gallati S., Ballmann M.Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax. 2010 Jul;65(7):594-9. doi: 10.1136/thx.2009.125088.
15. Register of patients with cystic fibrosis in the Russian Federation 2021 / Edd S. A. Krasovsky, M. A. Starinova, A. Yu. Voronkova, E. L. Amelina, N. Yu. Kashirskaya, E. I. Kondratyeva, L. P. Nazarenko. Moscow. Publishing House “MEDPRACTIKA-M”, 2023, 95 p. (in Russ.)@@ Регистр больных муковисцидозом в Российской Федерации. 2021 год./ Под редакцией С. А. Красовского, М. А. Стариновой, А. Ю. Воронковой, Е. Л. Амелиной, Н. Ю. Каширской, Е. И. Кондратьевой, Л. П. Назаренко - М.: ИД «МЕДПРАКТИКА-М», 2023, 95 с.
Review
For citations:
Melyanovskaya Yu.L., Kondratyeva E.I. The first described pathogenic variant c.2617G>T of the CFTR gene. Archives of Pediatrics and Pediatric Surgery. 2024;2(1):142-147. (In Russ.) https://doi.org/10.31146/2949-4664-apps-2-1-142-147
Views:
178
Email this article 